Switch theme
Sign up to access all valuation multiples
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
1999
11
LTM Revenue $3.6M
LTM EBITDA -$3.5M
$37.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascelia Pharma has a last 12-month revenue (LTM) of $3.6M and a last 12-month EBITDA of -$3.5M.
In the most recent fiscal year, Ascelia Pharma achieved revenue of n/a and an EBITDA of -$7.9M.
Ascelia Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascelia Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $3.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.5M | XXX | -$7.9M | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$3.5M | XXX | -$7.0M | XXX | XXX | XXX |
| EBIT Margin | -98% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.2M | XXX | -$8.3M | XXX | XXX | XXX |
| Net Margin | -116% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ascelia Pharma's stock price is SEK 4 (or $0).
Ascelia Pharma has current market cap of SEK 397M (or $40.9M), and EV of SEK 367M (or $37.8M).
See Ascelia Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.8M | $40.9M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ascelia Pharma has market cap of $40.9M and EV of $37.8M.
Ascelia Pharma's trades at n/a EV/Revenue multiple, and -4.8x EV/EBITDA.
Equity research analysts estimate Ascelia Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ascelia Pharma has a P/E ratio of -9.8x.
See valuation multiples for Ascelia Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40.9M | XXX | $40.9M | XXX | XXX | XXX |
| EV (current) | $37.8M | XXX | $37.8M | XXX | XXX | XXX |
| EV/Revenue | 10.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.8x | XXX | -4.8x | XXX | XXX | XXX |
| EV/EBIT | -10.8x | XXX | -5.4x | XXX | XXX | XXX |
| EV/Gross Profit | 11.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.8x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | -11.2x | XXX | -5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAscelia Pharma's last 12 month revenue growth is 84%
Ascelia Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.6M for the same period.
Ascelia Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ascelia Pharma's rule of X is 112% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ascelia Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 84% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -91% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 112% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascelia Pharma acquired XXX companies to date.
Last acquisition by Ascelia Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascelia Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ascelia Pharma founded? | Ascelia Pharma was founded in 1999. |
| Where is Ascelia Pharma headquartered? | Ascelia Pharma is headquartered in Sweden. |
| How many employees does Ascelia Pharma have? | As of today, Ascelia Pharma has 11 employees. |
| Who is the CEO of Ascelia Pharma? | Ascelia Pharma's CEO is Mr. Magnus Corfitzen. |
| Is Ascelia Pharma publicy listed? | Yes, Ascelia Pharma is a public company listed on STO. |
| What is the stock symbol of Ascelia Pharma? | Ascelia Pharma trades under ACE ticker. |
| When did Ascelia Pharma go public? | Ascelia Pharma went public in 2019. |
| Who are competitors of Ascelia Pharma? | Similar companies to Ascelia Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ascelia Pharma? | Ascelia Pharma's current market cap is $40.9M |
| What is the current revenue of Ascelia Pharma? | Ascelia Pharma's last 12 months revenue is $3.6M. |
| What is the current revenue growth of Ascelia Pharma? | Ascelia Pharma revenue growth (NTM/LTM) is 84%. |
| What is the current EV/Revenue multiple of Ascelia Pharma? | Current revenue multiple of Ascelia Pharma is 10.5x. |
| Is Ascelia Pharma profitable? | Yes, Ascelia Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ascelia Pharma? | Ascelia Pharma's last 12 months EBITDA is -$3.5M. |
| What is Ascelia Pharma's EBITDA margin? | Ascelia Pharma's last 12 months EBITDA margin is -98%. |
| What is the current EV/EBITDA multiple of Ascelia Pharma? | Current EBITDA multiple of Ascelia Pharma is -10.8x. |
| What is the current FCF of Ascelia Pharma? | Ascelia Pharma's last 12 months FCF is -$3.4M. |
| What is Ascelia Pharma's FCF margin? | Ascelia Pharma's last 12 months FCF margin is -94%. |
| What is the current EV/FCF multiple of Ascelia Pharma? | Current FCF multiple of Ascelia Pharma is -11.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
